We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Mitral Valve Surgery Shows Improved Survival Rates

By HospiMedica International staff writers
Posted on 31 May 2012
A new study has found that outcomes following mitral valve surgery have significantly improved over the years among patients with mitral regurgitation.

Researchers at Yale School of Medicine (Yale, New Haven, CT, USA) conducted a study that analyzed the 30-day and one-year mortality rate in 157,032 US Medicare fee-for-service (FFS) patients 65 years or older, who underwent mitral valve surgery between 1999 and 2008. More...
They then denoted hospitalization rates per 100,000 beneficiary years--ascertained through corresponding inpatient and vital status files--for isolated mitral valve surgery, 30-day readmission, 30-day mortality, and one-year mortality outcomes, adjusting for age, sex, race, and comorbidities.

The results showed that during the study period, the overall rate of mitral valve surgery per 100K beneficiary-years declined from 56 to 51, and the proportion of patients undergoing mitral valve repair (versus replacement) increased from 24.7% to 46.9%. For isolated mitral valve surgery, there were significant declines in risk-adjusted 30-day mortality (8.1% to 4.2%) and one-year mortality (15.3% to 9.2%), and a slight decline in risk-adjusted 30-day readmission (23% compared to 21%). Overall, mortality rates decreased in all age, sex, and race subgroups, and among patients undergoing mitral valve repair or replacement, but remained higher among patients aged 85 years, women, and nonwhites. The study was published online before print on May 10, 2012, in Circulation: Cardiovascular Quality and Outcomes.

“The marked reduction in mortality after mitral valve surgery over time is an encouraging trend for cardiac surgery. Several factors may be responsible, including improved surgical techniques, and lower rates of post-operative complications,” said lead author John Dodson, MD, a postdoctoral fellow in cardiology and geriatrics at Yale. “There remain differences in the rate of mitral valve surgery performed, and mortality outcomes, among sex and race subgroups that deserve further investigation.”

Mitral regurgitation, the most common form of valvular heart disease, is a disorder of the heart in which the mitral valve does not close properly, causing blood expelled from the left ventricle through the mitral valve and into the left atrium (when the left ventricle contracts) to return back into the left atrium through the leaky valve.

Related Links:

Yale School of Medicine




Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammo DR Retrofit Solution
DR Retrofit Mammography
Adjustable Mobile Barrier
M-458
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.